

## October 17, 2008 - Frequently Asked Questions and Answers – (FAQs)

From time to time, Investor Relations will provide FAQs on various topics of interest. The following is a recent FAQ.

### Q What are the IMS prescription volumes for VYTORIN and ZETIA?

#### A U.S. Total Prescription Volume (000's)

|                                       | Jan.<br>2008 | Feb.<br>2008 | March<br>2008 | April<br>2008 | May<br>2008 | June<br>2008 |
|---------------------------------------|--------------|--------------|---------------|---------------|-------------|--------------|
| Cholesterol Management Market         | 20,519       | 19,042       | 19,788        | 19,645        | 19,910      | 19,403       |
| Total Merck/Schering-Plough Franchise | 3,226        | 2,790        | 2,820         | 2,507         | 2,479       | 2,351        |
| VYTORIN                               | 1,851        | 1,607        | 1,619         | 1,428         | 1,412       | 1,330        |
| ZETIA                                 | 1,375        | 1,183        | 1,201         | 1,079         | 1,067       | 1,022        |

|                                       | July<br>2008 | Aug.<br>2008 | Sept.<br>2008 |
|---------------------------------------|--------------|--------------|---------------|
| Cholesterol Management Market         | 20,292       | 19,666       | 19,923        |
| Total Merck/Schering-Plough Franchise | 2,376        | 2,233        | 2,171         |
| VYTORIN                               | 1,339        | 1,249        | 1,202         |
| ZETIA                                 | 1,038        | 984          | 969           |

Source: IMS' *National Prescription Audit Plus (NPA+)* as of October 15, 2008 which includes routine refinements by IMS to previously published data.

**DISCLOSURE NOTICE:** The information in the frequently asked questions included in this FAQ, and in other written and oral statements about Schering-Plough and its business made by Schering-Plough or its officers from time to time, includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to prescription trends for VYTORIN and ZETIA.

Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces (such as customer buying patterns); economic factors; product availability; patent and other intellectual property protection; current and future branded, generic or over-the-counter competition; the timing and outcomes of the regulatory process; the timing and outcomes of clinical trials; and prescriber, patient and media reaction to data obtained from post-marketing clinical trials, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A. "Risk Factors" in the second quarter 2008 10-Q, filed August 1, 2008.